With prospects for an AstraZeneca Plc deal falling apart, Pfizer Inc. Chief Executive Officer Ian Read is facing a new question from investors: What now?
Jeff Jonas, an analyst at Gabelli & Co., says he recommends shares of Bristol-Myers Squibb and Watson Pharmaceuticals. Jonas talks with Bloomberg's Ken Prewitt, Tom Keene and Sara Eisen on Bloomberg Radio's "Bloomberg Surveillance."
Mylan Inc., the biggest U.S. generic-drug maker, was rejected in its bid to buy Meda AB, the Swedish pharmaceuticals maker valued at about $4.5 billion.
Covidien Plc., a maker of surgical products and drugs, plans to spin off its pharmaceuticals division into a separate company that would be better able to compete in the growing pain-management area.
"I'm surprised at AstraZeneca."
- Jeff Jonas on May 25, 2014
Bloomberg Surveillance: Foley and Jonas
Gabelli’s Jonas Says Pfizer Deal Will Get Done (Audio)
Gabelli’s Jonas Says CVS Can Maintain Current Growth (Audio)
Gabelli's Jonas Discusses Allegran, Valeant Deal (Audio)
Jonas Discusses Cigna Pharmacy-Benefits Division